LifeStance Health Group stock
LFSTNASDAQLifeStance Health Group, Inc., HealthcareISIN US53228F1012
57Score 57 out of 100, Neutral
Price and trend
85 / 100
Price history
+120% in one yearThe chart shows daily closes over 5 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 47% above it.
Since December 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 64).
The price is 3.1% below its 52-week high. Largest decline in 5 years: 87% (July 2021 to August 2025).
Chart figures for advanced users
- SMA 50$12.77
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$9.64
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)64
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$6.18
- The lowest closing price of the last twelve months.
- Resistance$14.60
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- LifeStance Health Group, Inc. belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $5.38B, is number 17 of 56 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $1.71B (up 20%) and adjusted earnings per share of $0.16 (up 558.8%).
- MEQIRI Score 57 out of 100 (Neutral): rank 319 of 714 in Healthcare, median 53.
Show more
- Our model puts fair value at $6.02, with the price 139% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 30.4% a year since 2020, Medical (Care Facilities) median 9.2%.Growth 70
- Earnings turn into cashFree cash flow 300% of earnings over the last 12 months.
- Analysts expect strong earnings growthUp 44.6% a year through 2028 (estimates from 5 analysts).Growth 70
Weaknesses
- Above fair valuePrice 139% above the fair value of $6.02.Valuation 22
- Interest barely coveredOperating profit covers interest only 2.1 times.Stability 55
Its standout strengths are momentum and technical analysis, while profitability and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price up very strongly over the past year
- weak fundamentals
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Significantly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $4.30 and expensive above $10.04 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $8.49 (cash-flow model) and $3.56 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $5.39, at 7.8% it would be $6.97.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.4).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 22.6% on the twelve months before. Revenue has grown strongly since 2019, at around 37% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 32%, operating 2%, net 1%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 24 Feb 2027in 104 days
- Last reported
- 5 Nov 2026EPS reported $0.06 (expected $0.04)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.16+1.0%
- Revenue
- $1.71B0.0%
- Earnings per share
- $0.220.0%
- Revenue
- $1.96B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +4.5%Guidance raised again across all metrics: revenue of $1.685 billion to $1.725 billion (up $45 million at the midpoint) and adjusted EBITDA up $15 million.
“In terms of our outlook for the full year, we are raising our revenue range by $45 million at the midpoint to $1.685 billion to $1.725 billion. The midpoint of the revenue guidance range implies a growth rate of 20% for the full year.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 6 insiders sold, $387.85M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Tpg Gp A, LlcSale
11 Sept 2026, Major holder
- Shares
- 18,409,705
- Price
- $12.29
- Value
- $226.26M
- Paunovich VukasinSale
2 Sept 2026, Chief Technology Officer
- Shares
- 42,067
- Price
- $12.87
- Value
- $541,402
- DeLuca TeresaSale
14 Aug 2026, Board
- Shares
- 7,500
- Price
- $12.68
- Value
- $95,100
Show 6 more
- DeLuca TeresaSale
13 Aug 2026, Board
- Shares
- 20,441
- Price
- $12.23
- Value
- $249,993
- Burdick Kenneth ASale
11 Aug 2026, Board
- Shares
- 500,000
- Price
- $11.51
- Value
- $5.76M
- Paunovich VukasinSale
10 Aug 2026, Chief Technology Officer
- Shares
- 44,394
- Price
- $10.85
- Value
- $481,675
- Tpg Gp A, LlcSale
10 Aug 2026, Major holder
- Shares
- 13,643,207
- Price
- $10.62
- Value
- $144.89M
- Miller Lisa KSale
10 Aug 2026, Chief Operating Officer
- Shares
- 47,912
- Price
- $10.85
- Value
- $519,845
- Bessler RobertSale
26 Jun 2026, Board
- Shares
- 894,337
- Price
- $10.13
- Value
- $9.06M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at LifeStance Health Group
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 57
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- PACS GroupPACS $7.95B67
- ChemedCHE $7.17B75
- Fortis HealthcareFORTIS.NS $6.22B53
- Concentra Group Holdings ParentCON $5.5B69
- Option Care HealthOPCH $4.75B64
- Hims & Hers HealthHIMS $4.68B35
- MedicoverMCOV-B.ST $4.02B62
- Acadia HealthcareACHC $3.61B47
ETFs that hold LifeStance Health Group
Held by 15 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Telemedicine & Digital Health UCITS ETFDDOC | 2.91% | 0.68% | €5.31M |
| iShares Ageing Population UCITS ETF2B77 | 0.30% | 0.40% | €807M |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.22% | 0.30% | €2.28B |
Show 5 more
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.13% | 0.30% | €185.82M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.12% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.12% | 0.30% | €2.17B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.03% | 0.35% | €8.19B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.03% | 0.43% | €2.48B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.